Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioceres Crop Solutions (BIOX) Non-Current Deffered Revenue (2021 - 2025)

Bioceres Crop Solutions' Non-Current Deffered Revenue history spans 5 years, with the latest figure at $1.4 million for Q2 2025.

  • On a quarterly basis, Non-Current Deffered Revenue fell 25.36% to $1.4 million in Q2 2025 year-over-year; TTM through Jun 2025 was $1.4 million, a 25.36% decrease, with the full-year FY2025 number at $1.4 million, down 25.36% from a year prior.
  • Non-Current Deffered Revenue hit $1.4 million in Q2 2025 for Bioceres Crop Solutions, down from $1.9 million in the prior quarter.
  • Over the last five years, Non-Current Deffered Revenue for BIOX hit a ceiling of $2.1 million in Q2 2023 and a floor of $992000.0 in Q2 2022.
  • Historically, Non-Current Deffered Revenue has averaged $1.5 million across 5 years, with a median of $1.4 million in 2025.
  • Biggest five-year swings in Non-Current Deffered Revenue: surged 107.44% in 2023 and later dropped 25.36% in 2025.
  • Tracing BIOX's Non-Current Deffered Revenue over 5 years: stood at $1.2 million in 2021, then dropped by 14.85% to $992000.0 in 2022, then skyrocketed by 107.44% to $2.1 million in 2023, then dropped by 6.45% to $1.9 million in 2024, then dropped by 25.36% to $1.4 million in 2025.
  • Business Quant data shows Non-Current Deffered Revenue for BIOX at $1.4 million in Q2 2025, $1.9 million in Q2 2024, and $2.1 million in Q2 2023.